The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Drugging the p53 pathway: understanding the route to clinical efficacy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The TP53 gene is inactivated by mutation in about half of all human cancers [1, 3, 4].”
From Evolutionary history of the p53 family DNA-binding domain: insights from an Alvinella pompejana homolog (2022) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Konopleva, M. Y., Milella, M., Ruvolo, P. P., Watts, J. C., Ricciardi, M. R., Korchin, B., McQueen, T. J., BORNMANN, W. G., Tsao, T., Bergamo, P., et al. (2011) · Leukemia · doi:10.1038/leu.2011.287 · Cited by 146
RetractedVogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Self-citationLane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Self-citationIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
p53 Has a Direct Apoptogenic Role at the Mitochondria
Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P., & Moll, U. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00050-9 · Cited by 1,777
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,240
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishimori, H., Tamai, K., Tokino, T., Nakamura, Y., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00073-8 · Cited by 1,172
The antioxidant function of the p53 tumor suppressor
Sablina, A. A., Budanov, A. V., Ilyinskaya, G. V., Agapova, L. S., Kravchenko, J. E., & Chumakov, P. M. (2005) · Nature Medicine · doi:10.1038/nm1320 · Cited by 1,121
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Schafmeister, C. E., Po, J., & Verdine, G. L. (2000) · Journal of the American Chemical Society · doi:10.1021/ja000563a · Cited by 1,037
Konopleva, M., Contractor, R., Tsao, T., Samudio, I., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,023
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Self-citationRoberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S. Z., Huang, D. C. S., Xiong, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 830
Modelling Myc inhibition as a cancer therapy
Soucek, L., Whitfield, J., Martins, C. P., Finch, A. J., Murphy, D. J., Sodir, N. M., Karnezis, A. N., Swigart, L. B., Nasi, S., & Evan, G. I. (2008) · Nature · doi:10.1038/nature07260 · Cited by 817
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Chen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis
D'Orazi, G., Cecchinelli, B., Bruno, T., Manni, I., Higashimoto, Y., Saito, S., Gostissa, M., Coen, S., Marchetti, A., Del Sal, G., et al. (2002) · Nature Cell Biology · doi:10.1038/ncb714 · Cited by 681
ASPP Proteins Specifically Stimulate the Apoptotic Function of p53
Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J.-K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., & Lu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00367-7 · Cited by 664
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
Chang, Y. S., Graves, B., Guerlavais, V., Tovar, C., Packman, K., To, K.-H., Olson, K. A., Kesavan, K., Gangurde, P., Mukherjee, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303002110 · Cited by 660
Chalcones: An Update on Cytotoxic and Chemoprotective Properties
Go, M., Wu, X., & Liu, X. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867053363153 · Cited by 619
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2
Hofmann, T. G., Möller, A., Sirma, H., Zentgraf, H., Taya, Y., Dröge, W., Will, H., & Schmitz, M. L. (2002) · Nature Cell Biology · doi:10.1038/ncb715 · Cited by 592
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Waugh, D. F. (1954) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60210-7 · Cited by 566
Rudin, C. M., Hann, C. L., Garon, E. B., Ribeiro de Oliveira, M., Bonomi, P. D., Camidge, D. R., Chu, Q., Giaccone, G., Khaira, D., Ramalingam, S. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3090 · Cited by 564
Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide
Bernal, F., Tyler, A. F., Korsmeyer, S. J., Walensky, L. D., & Verdine, G. L. (2007) · Journal of the American Chemical Society · doi:10.1021/ja0693587 · Cited by 556
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally
García‐Cao, I., García‐Cao, M., Martín‐Caballero, J., Criado, L. M., Klatt, P., Flores, J. M., Weill, J., Blasco, M. A., & Serrano, M. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf595 · Cited by 529
Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator
Lain, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., McCarthy, A., Appleyard, V., Murray, K. E., Baker, L., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.03.004 · Cited by 522
Self-citationAcetylation of p53 inhibits its ubiquitination by Mdm2
Li, M., Luo, J., Brooks, C. L., & Gu, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200578200 · Cited by 503
Sawkar, A. R., Cheng, W.-C., Beutler, E., Wong, C.-H., Balch, W. E., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192582899 · Cited by 503
Structure–function–rescue: the diverse nature of common p53 cancer mutants
Joerger, A. C., & Fersht, A. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210291 · Cited by 434
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 432
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia
Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A., Fairlie, W. D., Izon, D. J., Zuber, J., Rappaport, A. R., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 423
The Restriction Point of the Cell Cycle
Blagosklonny, M. V., & Pardee, A. B. (2002) · Cell Cycle · doi:10.4161/cc.1.2.108 · Cited by 412
Li, L., Wang, L., Li, L., Wang, Z., Ho, Y., McDonald, T., Holyoake, T. L., Chen, W., & Bhatia, R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.020 · Cited by 410
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M., Nissim-Rafinia, M., Blau, H., Rivlin, J., Aviram, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61168-x · Cited by 403
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX
Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900947106 · Cited by 391
Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins
Konopleva, M., Konoplev, S., Hu, W., Zaritskey, A., Afanasiev, B., & Andreeff, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402608 · Cited by 389
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
A Stapled BID BH3 Helix Directly Binds and Activates BAX
Walensky, L. D., Pitter, K., Morash, J., Oh, K. J., Barbuto, S., Fisher, J., Smith, E., Verdine, G. L., & Korsmeyer, S. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.020 · Cited by 383
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
Self-citationDesign of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00374-5 · Cited by 363
Self-citationAcquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Yecies, D., Carlson, N. E., Deng, J., & Letai, A. (2010) · Blood · doi:10.1182/blood-2009-07-233304 · Cited by 360
Robertson, K. D., & Jones, P. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.11.6457 · Cited by 352
Vo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348
Jackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327
the CPNDS Consortium, Ross, C. J. D., Katzov-Eckert, H., Dubé, M.-P., Brooks, B., Rassekh, S. R., Barhdadi, A., Feroz-Zada, Y., Visscher, H., Brown, A. M. K., et al. (2009) · Nature Genetics · doi:10.1038/ng.478 · Cited by 327
Orner, B. P., Ernst, J. T., & Hamilton, A. D. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0025548 · Cited by 320
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 295
Sakaguchi, K., Saito, S., Higashimoto, Y., Roy, S., Anderson, C. W., & Appella, E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.13.9278 · Cited by 293
Valente, L. J., Gray, D. H. D., Michalak, E. M., Pinon-Hofbauer, J., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 291
Zhao, Y., Yu, S., Sun, W., Liu, L., Lu, J., McEachern, D., Shargary, S., Bernard, D., Li, X., Zhao, T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005708 · Cited by 290
MacCallum, D. E., Melville, J., Frame, S., Watt, K., Anderson, S., Gianella-Borradori, A., Lane, D. P., & Green, S. R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0233 · Cited by 288
Self-citationA Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
Stoll, R., Renner, C., Hansen, S., Palme, S., Klein, C., Belling, A., Zeslawski, W., Kamionka, M., Rehm, T., Mühlhahn, P., et al. (2001) · Biochemistry · doi:10.1021/bi000930v · Cited by 275
Komarova, E. A. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1391 · Cited by 273
Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics
Vassilev, L. T. (2004) · Cell Cycle · doi:10.4161/cc.3.4.801 · Cited by 271
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis.
Kracikova, M., Akiri, G., George, A., Sachidanandam, R., & Aaronson, S. A. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.155 · Cited by 261
Bergamaschi, D., Samuels, Y., Sullivan, A., Zvelebil, M., Breyssens, H., Bisso, A., Del Sal, G., Syed, N., Smith, P., Gasco, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1879 · Cited by 259
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo
Ringshausen, I., O'Shea, C. C., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.010 · Cited by 256
Terphenyl‐Based Helical Mimetics That Disrupt the p53/HDM2 Interaction
Yin, H., Lee, G., Park, H. S., Payne, G. A., Rodriguez, J. M., Sebti, S. M., & Hamilton, A. D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462316 · Cited by 255
Sermet-Gaudelus, I., Boeck, K. D., Casimir, G. J., Vermeulen, F., Leal, T., Mogenet, A., Roussel, D., Fritsch, J., Hanssens, L., Hirawat, S., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0137oc · Cited by 248
Picksley, S. M., Vojtĕsek, B., Sparks, A., & Lane, D. P. (1994) · PubMed · Cited by 238
Self-citationHalogen-Enriched Fragment Libraries as Leads for Drug Rescue of Mutant p53
Wilcken, R., Liu, X., Zimmermann, M. O., Rutherford, T. J., Fersht, A. R., Joerger, A. C., & Boeckler, F. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301056a · Cited by 235
Small molecule induced reactivation of mutant p53 in cancer cells
Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I. S., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 234
Coll-Mulet, L., Iglesias-Serret, D., Santidrián, A. F., Cosialls, A. M., de Frias, M., Castaño, E., Campàs, C., Barragán, M., de Sevilla, A. F., Domingo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3273 · Cited by 234
mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234
In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide
Ji, Y., Majumder, S., Millard, M., Borra, R., Bi, T., Elnagar, A. Y., Neamati, N., Shekhtman, A., & Camarero, J. A. (2013) · Journal of the American Chemical Society · doi:10.1021/ja405108p · Cited by 233
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230
Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 228
Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53
Wassman, C. D., Baronio, R., Demir, Ö., Wallentine, B. D., Chen, C.-K., Hall, L. V., Salehi, F., Lin, D.-W., Chung, B. P., Wesley Hatfield, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2361 · Cited by 223
Stapled Peptides with Improved Potency and Specificity That Activate p53
Brown, C. J., Quah, S. T., Jong, J., Goh, A. M., Chiam, P. C., Khoo, K. H., Choong, M. L., Lee, M. A., Yurlova, L., Zolghadr, K., et al. (2013) · ACS Chemical Biology · doi:10.1021/cb3005148 · Cited by 209
Self-citationPrognostic impact and targeting of CRM1 in acute myeloid leukemia
Kojima, K., Kornblau, S. M., Ruvolo, V., Dilip, A., Duvvuri, S., Davis, R. E., Zhang, M., Wang, Z., Coombes, K. R., Zhang, N., et al. (2013) · Blood · doi:10.1182/blood-2012-08-447581 · Cited by 206
Michalak, E. M., Villunger, A., Adams, J. M., & Strasser, A. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.16 · Cited by 205
Introducing sense into nonsense in treatments of human genetic diseases
Linde, L., & Kerem, B. (2008) · Trends in Genetics · doi:10.1016/j.tig.2008.08.010 · Cited by 205
Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression
Auld, D. S., Thorne, N., Maguire, W. F., & Inglese, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813345106 · Cited by 204
Activation of p53 by MDM2 Antagonists Can Protect Proliferating Cells from Mitotic Inhibitors
Carvajal, D., Tovar, C., Yang, H., Vu, B. T., Heimbrook, D. C., & Vassilev, L. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3576 · Cited by 201
The p53 response to ionising radiation in adult and developing murine tissues.
MacCallum, D. E., Hupp, T. R., Midgley, C. A., Stuart, D., Campbell, S. J., Harper, A., Walsh, F. S., Wright, E. G., Balmain, A., Lane, D. P., et al. (1996) · PubMed · Cited by 200
Self-citationIdentification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 194
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193
Michaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 189
Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning Profiles
Sawkar, A. R., Adamski-Werner, S. L., Cheng, W.-C., Wong, C.-H., Beutler, E., Zimmer, K.-P., & Kelly, J. W. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.09.007 · Cited by 183
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124
Auld, D. S., Lovell, S., Thorne, N., Lea, W. A., Maloney, D. J., Shen, M., Rai, G., Battaile, K. P., Thomas, C. J., Simeonov, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909141107 · Cited by 173
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Lu, M., Breyssens, H., Salter, V., Zhong, S., Hu, Y., Baer, C., Ratnayaka, I., Sullivan, A., Brown, N. R., Endicott, J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.013 · Cited by 166
Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 165
Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction
Rew, Y., Sun, D., Gonzalez-Lopez De Turiso, F., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Deignan, J., Fox, B. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300354j · Cited by 165
Hdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Exploiting cancer cell cycling for selective protection of normal cells.
Blagosklonny, M. V., & Pardee, A. B. (2001) · PubMed · Cited by 160
Secchiero, P., Barbarotto, E., Tiribelli, M., Zerbinati, C., di Iasio, M. G., Gonelli, A., Cavazzini, F., Campioni, D., Fanin, R., Cuneo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4465 · Cited by 158
Hardcastle, I. R., Liu, J., Valeur, E., Watson, A. F., Ahmed, S. U., Blackburn, T. J., Bennaceur, K., Clegg, W., Drummond, C. J., Endicott, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1011929 · Cited by 154
Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations
Nikolova, P. V., Wong, K., DeDecker, B., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 152
Systematic Mutational Analysis of Peptide Inhibition of the p53–MDM2/MDMX Interactions
Li, C. V., Pazgier, M., Li, C., Yuan, W., Liu, M., Wei, G., Lu, W., & Lu, W. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.03.005 · Cited by 151
Allen, J. G., Bourbeau, M. P., Wohlhieter, G. E., Bartberger, M. D., Michelsen, K., Hungate, R. W., Gadwood, R. C., Gaston, R. D., Evans, B., Mann, L. W., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900681h · Cited by 149
Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
Floquet, C., Deforges, J., Rousset, J.-P., & Bidou, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1277 · Cited by 144
Brachmann, R. K., Yu, K., Eby, Y., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 142
Puca, R., Nardinocchi, L., Givol, D., & D’Orazi, G. (2010) · Oncogene · doi:10.1038/onc.2010.183 · Cited by 141
Choong, M. L., Yang, H. C., Lee, M. A., & Lane, D. P. (2009) · Cell Cycle · doi:10.4161/cc.8.17.9503 · Cited by 141
Self-citationChêne, P., Fuchs, J. P., Bohn, J. A., Garcı́a-Echeverrı́a, C., Furet, P., & Fabbro, D. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3738 · Cited by 139
Czarna, A., Beck, B., Srivastava, S., Popowicz, G. M., Wolf, S., Huang, Y., Biśta, M., Holak, T. A., & Dömling, A. S. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201001343 · Cited by 137
The missing Zinc: p53 misfolding and cancer
Loh, S. N. (2010) · Metallomics · doi:10.1039/c003915b · Cited by 137
Held, J. M., Danielson, S. R., Behring, J. B., Atsriku, C., Britton, D. J., Puckett, R., Schilling, B., Campisi, J., Benz, C. C., & Gibson, B. W. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900643-mcp200 · Cited by 137
Okamoto, T., Zobel, K., Fedorova, A., Quan, C., Yang, H., Fairbrother, W. J., Huang, D. C. S., Smith, B. J., Deshayes, K., & Czabotar, P. E. (2013) · ACS Chemical Biology · doi:10.1021/cb3005403 · Cited by 136
Davids, M. S., Deng, J., Wiestner, A. U., Lannutti, B. J., Wang, L., Wu, C. J., Wilson, W. H., Brown, J. R., & Letai, A. G. (2012) · Blood · doi:10.1182/blood-2012-02-414060 · Cited by 136
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Maerken, T. V., Ferdinande, L., Taildeman, J., Lambertz, I., Yigit, N., Vercruysse, L., Rihani, A., Michaelis, M., Cinatl, J. J., Cuvelier, C. A., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp355 · Cited by 125
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3168 · Cited by 118
Puca, R., Nardinocchi, L., Porru, M., Simon, A. J., Rechavi, G., Leonetti, C., Givol, D., & D’Orazi, G. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15642 · Cited by 117
Policing of oncogene activity by p53
Efeyan, A., García-Cao, I., Herranz, D., Velasco-Miguel, S., & Serrano, M. (2006) · Nature · doi:10.1038/443159a · Cited by 116
DNA Binding Cooperativity of p53 Modulates the Decision between Cell-Cycle Arrest and Apoptosis
Schlereth, K., Beinoraviciute-Kellner, R., Zeitlinger, M. K., Bretz, A. C., Sauer, M., Charles, J. P., Vogiatzi, F., Leich, E., Samans, B., Eilers, M., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.037 · Cited by 113
Basse, N., Kaar, J. L., Settanni, G., Joerger, A. C., Rutherford, T. J., & Fersht, A. R. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2009.12.011 · Cited by 113
Happo, L., Cragg, M. S., Phipson, B., Haga, J. M., Jansen, E. S., Herold, M. J., Dewson, G., Michalak, E. M., Vandenberg, C. J., Smyth, G. K., et al. (2010) · Blood · doi:10.1182/blood-2010-04-280818 · Cited by 112
Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA
Veprintsev, D. B., & Fersht, A. R. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1040 · Cited by 109
Kayalı, R., Ku, J., Khitrov, G., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds223 · Cited by 106
Gannon, H. S., Woda, B. A., & Jones, S. N. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.011 · Cited by 105
Lehmann, B. D., McCubrey, J. A., Jefferson, H. S., Paine, M. S., Chappell, W. H., & Terrian, D. M. (2007) · Cell Cycle · doi:10.4161/cc.6.5.3901 · Cited by 105
Blank, J. L., Liu, X. J., Cosmopoulos, K., Bouck, D. C., Garcia, K., Bernard, H., Tayber, O., Hather, G., Liu, R., Narayanan, U., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1729 · Cited by 104
Michaelis, M., Rothweiler, F., Klassert, D., von Deimling, A., Riecken, K., Fehse, B., Kammerer, B., Doerr, H. W., & Cinatl, J. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1856 · Cited by 101
Kojima, K., Konopleva, M. Y., Samudio, I. J., Schober, W. D., Bornmann, W. G., & Andreeff, M. (2006) · Cell Cycle · doi:10.4161/cc.5.23.3520 · Cited by 101
Gutekunst, M., Oren, M., Weilbacher, A., Dengler, M. A., Markwardt, C., Thomale, J., Aulitzky, W. E., & van der Kuip, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019198 · Cited by 100
Rooswinkel, R. W., van de Kooij, B., Verheij, M., & Borst, J. G. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.109 · Cited by 91
Jiang, D., Brady, C. A., Johnson, T. M., Lee, E. Y., Park, E. J., Scott, M. P., & Attardi, L. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111245108 · Cited by 91
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Iancu-Rubin, C., Mosoyan, G., Glenn, K., Gordon, R. E., Nichols, G. L., & Hoffman, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.012 · Cited by 90
Galatin, P. S., & Abraham, D. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm034182u · Cited by 90
Dastidar, S. G., Lane, D. P., & Verma, C. S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804289g · Cited by 87
Self-citationLong, J., Parkin, B. L., Ouillette, P. D., Bixby, D. L., Shedden, K., Erba, H. P., Wang, S., & Malek, S. N. (2010) · Blood · doi:10.1182/blood-2010-01-261628 · Cited by 87
Bertamino, A., Soprano, M., Musella, S., Rusciano, M. R., Sala, M., Vernieri, E., Sarno, V. D., Limatola, A., Carotenuto, A., Cosconati, S., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400311n · Cited by 86
Nongenotoxic p53 Activation Protects Cells against S-Phase–Specific Chemotherapy
Kranz, D., & Dobbelstein, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1527 · Cited by 85
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
Garcia, D., Warr, M. R., Martins, C. P., Brown Swigart, L., Passegué, E., & Evan, G. I. (2011) · Genes & Development · doi:10.1101/gad.16722111 · Cited by 83
Tabe, Y., Sebasigari, D., Jin, L., Rudelius, M., Davies-Hill, T., Miyake, K., Miida, T., Pittaluga, S., & Raffeld, M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0399 · Cited by 83
McCormack, E., Haaland, I., Venås, G., Forthun, R. B., Huseby, S., Gausdal, G., Knappskog, S., Micklem, D., Lorens, J. B., Bruserud, Ø., et al. (2011) · Leukemia · doi:10.1038/leu.2011.315 · Cited by 83
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Kim, K. W., Albert, J. M., Hallahan, D. E., & Lü, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 83
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82
p53 DNA Binding Cooperativity Is Essential for Apoptosis and Tumor Suppression In Vivo
Timofeev, O. N., Schlereth, K., Wanzel, M., Braun, A., Nieswandt, B., Pagenstecher, A., Rosenwald, A., Elsässer, H., & Stiewe, T. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.008 · Cited by 82
The expression of iASPP in acute leukemias
Zhang, X., Wang, M., Zhou, C., Chen, S., & Wang, J. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.07.001 · Cited by 82
Shalom‐Feuerstein, R., Serror, L., Aberdam, É., Müller, F.-J., van Bokhoven, H., Wiman, K. G., Zhou, H., Aberdam, D., & Petit, I. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201753109 · Cited by 78
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
DNA damage response to the Mdm2 inhibitor Nutlin-3
Verma, R., Rigatti, M. J., Belinsky, G. S., Godman, C. A., & Giardina, C. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.020 · Cited by 77
Carter, B., Mak, D., Schober, W., Koller, E., Pinilla, C., Vassilev, L., Reed, J. C., & Andreeff, M. (2008) · Blood · doi:10.1182/blood-2009-03-212563 · Cited by 77
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
Supiot, S., Hill, R. P., & Bristow, R. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0442 · Cited by 77
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Valentine, J. M., Kumar, S., & Moumen, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-79 · Cited by 77
iASPP and Chemoresistance in Ovarian Cancers: Effects on Paclitaxel-Mediated Mitotic Catastrophe
Jiang, L., Siu, M. K. Y., Wong, O. G., Tam, K.-F., Lü, X., Lam, E. W. ‐., Ngan, H., Le, X., Wong, E. S. Y., Monteiro, L. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0588 · Cited by 75
Smart, P., Lane, E. B., Lane, D. P., Midgley, C., Vojtesek, B., & Laı́n, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203260 · Cited by 73
Self-citationTargeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
Ordering of the N-Terminus of Human MDM2 by Small Molecule Inhibitors
Michelsen, K., Jordan, J. B., Lewis, J. K., Long, A. M., Yang, E., Rew, Y., Zhou, J., Yakowec, P. S., Schnier, P. D., Huang, X., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja305839b · Cited by 72
Zhang, W., Konopleva, M., Burks, J. K., Dywer, K. C., Schober, W. D., Yang, J.-Y., McQueen, T. J., Hung, M.-C., & Andreeff, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-0878 · Cited by 70
Regulation of the p53 pathway by ubiquitin and related proteins
Hock, A., & Vousden, K. H. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.06.011 · Cited by 70
Kojima, K., Konopleva, M. Y., Tsao, T., Nakakuma, H., & Andreeff, M. (2008) · Blood · doi:10.1182/blood-2008-01-128611 · Cited by 69
Cheok, C. F., Dey, A., & Lane, D. P. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0161 · Cited by 69
Self-citationPRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
(2008) · PubMed Central · doi:10.3233/clo-2008-0440 · Cited by 68
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Sullivan, K. D., Padilla-Just, N., Henry, R. E., Porter, C. C., Kim, J., Tentler, J. J., Eckhardt, S. G., Tan, A. C., DeGregori, J., & Espinosa, J. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.965 · Cited by 67
Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding
Kaar, J. L., Basse, N., Joerger, A. C., Stephens, E., Rutherford, T. J., & Fersht, A. R. (2010) · Protein Science · doi:10.1002/pro.507 · Cited by 67
Pharmaceuticals Targeting Nonsense Mutations in Genetic Diseases
Rowe, S. M., & Clancy, J. P. (2009) · BioDrugs · doi:10.2165/00063030-200923030-00003 · Cited by 67
Kojima, K., Konopleva, M. Y., Samudio, I. J., Ruvolo, V. R., & Andreeff, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2712 · Cited by 65
Gutekunst, M., Mueller, T., Weilbacher, A., Dengler, M. A., Bedke, J., Kruck, S., Oren, M., Aulitzky, W. E., & van der Kuip, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2876 · Cited by 64
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
París, R., Henry, R. E., Stephens, S. J., McBryde, M., & Espinosa, J. M. (2008) · Cell Cycle · doi:10.4161/cc.6420 · Cited by 62
Saha, M. N., Jiang, H., & Chang, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.12535 · Cited by 61
Jones, R. J., Bjorklund, C. C., Baladandayuthapani, V., Kuhn, D. J., & Orlowski, R. Z. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0135 · Cited by 61
Discovery of a new small-molecule inhibitor of p53–MDM2 interaction using a yeast-based approach
Leão, M., Pereira, C., Bisio, A., Ciribilli, Y., Paiva, A. M. O., Machado, N., Palmeira, A., Fernandes, M. X., Sousa, E., Pinto, M. M. M., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.032 · Cited by 59
PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
Rökaeus, N., Shen, J., Eckhardt, I., Bykov, V. J. N., Wiman, K. G., & Wilhelm, M. (2010) · Oncogene · doi:10.1038/onc.2010.382 · Cited by 59
Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2
Kitagaki, J., Agama, K., Pommier, Y. G., Yang, Y., & Weissman, A. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0063 · Cited by 58
Cheok, C. F., Kua, N., Kaldis, P., & Lane, D. P. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.18 · Cited by 56
Self-citationLife or death: p53-induced apoptosis requires DNA binding cooperativity
Schlereth, K., Charles, J. P., Bretz, A. C., & Stiewe, T. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13595 · Cited by 54
Mechanism-specific signatures for small-molecule p53 activators
van Leeuwen, I. M. M., Higgins, M., Campbell, J., Brown, C. J., McCarthy, A. R., Pirrie, L., Westwood, N. J., & Laı́n, S. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15519 · Cited by 52
Zauli, G., Celeghini, C., Melloni, E., Voltan, R., Ongari, M., Tiribelli, M., di Iasio, M. G., Lanza, F., & Secchiero, P. (2012) · Haematologica · doi:10.3324/haematol.2012.062083 · Cited by 52
Scotcher, J., Clarke, D. J., Weidt, S. K., Mackay, C. L., Hupp, T. R., Sadler, P. J., & Langridge‐Smith, P. R. R. (2011) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-011-0088-x · Cited by 51
Cited by
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
The re-emergence of natural products for drug discovery in the genomics era
Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4510 · Cited by 2,572
Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D'Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,658
The Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
Metadata
- Authors
- Khoo, K. H., Verma, C. S., & Lane, D. P.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-02-28
- Volume
- 13
- Issue
- 3
- Pages
- 217-236
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028387032
- Cited by
- 719
- References
- 234
- FWCI
- 12.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.